In IM-resistant CML, pharmacological inhibition of ubiquitin-specific peptidase 47 (USP47) with P22077 reduces the percentage of CD34+CD38− cells in secondary BM transplantation and inhibits colony-forming activity of CD34+ cells from IM-resistant CML patients while sparing normal CD34+ cells [234]. Here, CD38 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.